How does Mounjaro help you lose weight?

What actually happens in your body when you inject Mounjaro?

Your gut produces two hormones after a meal, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both signal to your brain that food has arrived; both slow the speed at which your stomach passes food into the small intestine; both influence how much insulin is released. In most people with obesity, these signals are blunted, so the sense of fullness arrives late and fades quickly.

Tirzepatide, the active ingredient in Mounjaro, is a synthetic molecule designed to bind to and activate both receptors at the same time. The GLP-1 action reduces appetite and slows gastric emptying. The GIP action appears to amplify that effect and may also influence how fat tissue stores and releases energy, the precise interaction is still being studied. If you want a fuller explanation of how Mounjaro brings about weight loss through these two pathways, we cover the mechanism in detail on a dedicated page. The NHS patient information on tirzepatide describes the dual mechanism in accessible terms worth reading alongside this page.

The practical result: food feels satisfying sooner, hunger between meals is quieter, and the urge to eat past the point of fullness diminishes. None of this overrides your ability to eat, it shifts the biological signals that were making eating less feel harder than it should.

Does the way Mounjaro is taken affect how it works?

Mounjaro is injected once a week, under the skin, at a consistent day and time that suits your routine, many people find pairing it with a fixed moment, such as the evening before they restock the fridge, makes it easy to remember. Each pre-filled KwikPen is used once a week for four weeks; the pen stays refrigerated between 2 and 8°C, and the Patient Information Leaflet sets out the exact window for room-temperature storage if you need to take it away from home.

Treatment begins at 2.5 mg. That first dose exists to let your system adjust, not to drive significant weight loss, the therapeutic work builds as the prescriber moves you through 5 mg, 7.5 mg and higher strengths over the following months. The available UK strengths reach 15 mg. How quickly you move through them depends on how your body responds and what your prescriber judges appropriate; the schedule is individual, not automatic.

If you are thinking about how to structure the treatment period, our page on losing weight on Mounjaro covers the practical side in more detail.

What does the evidence say about how much weight Mounjaro can help people lose?

The pivotal trial is SURMOUNT-1, published in the New England Journal of Medicine. It randomised 2,539 adults with obesity but without type 2 diabetes, following them for 72 weeks. Participants taking 15 mg alongside a reduced-calorie diet and increased activity lost an average of around 20–21% of their body weight. Those on 10 mg lost roughly 19–20%; the 5 mg group averaged around 15%. All figures are averages from a clinical trial setting, individual results vary, and no specific outcome can be guaranteed.

In a more recent head-to-head trial, SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide 2.4 mg (the active ingredient in Wegovy) over 72 weeks in adults with obesity who did not have diabetes. NICE cited this and other indirect comparisons in its appraisal when recommending tirzepatide for NHS use.

The weight loss that trials document happens because of a real, sustained change in appetite and eating behaviour, not a temporary effect that reverses the moment the next dose is missed. That said, treatment works best alongside changes in diet and activity, and a prescriber is best placed to discuss what realistic progress might look like for you specifically. Our guide to whether Mounjaro is likely to help explores the individual factors in more depth.

Who is Mounjaro licensed to treat, and what should you know before starting?

In the UK, Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not determine whether treatment is appropriate, the prescriber considers your full health picture, including any medicines you already take and conditions that might affect suitability.

Mounjaro is not recommended during pregnancy, whilst breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, or certain pancreatic conditions, require careful prescriber discussion before starting. The most common side effects are gastrointestinal: nausea, loose stools, indigestion and constipation are frequently reported, particularly in the first weeks of a new dose, and generally settle as the body adjusts.

If you want to explore whether you meet the eligibility criteria and how the consultation works, the Mounjaro treatment overview on our site sets this out clearly. For a broader look at weight-loss treatment options, our weight management page compares the available medicines. The cost of private treatment is a common question too, a breakdown of what buying Mounjaro through a regulated UK pharmacy involves covers that ground. Our clinical team's approach is explained on the prescriber profile page if you'd like to understand who reviews consultations.